Artificial tears lead with 37.8% share as consumers seek familiar relief, easier pharmacy access, and formulations suited to repeat use

ROCKVILLE, Md., September 15, 2026 — Eye-drop safety and formulation quality remain important considerations in the non-prescription eye-care market. On January 22, 2024, the U.S. Food and Drug Administration published an amendment concerning a nationwide recall of certain lubricant and multi-symptom eye drops distributed in the United States, underscoring the importance of manufacturing controls and consumer confidence in ophthalmic products.

Against this backdrop, the global OTC Dry Eye Drops Market is estimated at USD 4.9 billion in 2026, up from USD 4.6 billion in 2025, according to Fact.MR. The market is forecast to reach USD 8.8 billion by 2036, expanding at a 6.0% CAGR during 2026–2036 and creating an absolute dollar opportunity of USD 3.9 billion.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=15752

Why Is Demand for OTC Dry Eye Drops Increasing?

The OTC category benefits from a straightforward consumer proposition. People experiencing occasional or recurring dryness can purchase lubricating drops without a prescription, making pharmacies and online channels important points of access.

Daily screen exposure, workplace routines, contact-lens use, environmental conditions, and age-related irritation create repeated occasions for dry-eye relief. For many consumers, artificial tears remain the first product considered because the purpose is easy to understand.

The competitive issue is becoming more specific. Consumers are increasingly comparing preservative-free options, packaging convenience, dosing formats, and perceived comfort rather than simply choosing the lowest-priced eye drop.

Fact.MR estimates that the OTC Dry Eye Drops Market will add approximately USD 3.9 billion in value between 2026 and 2036.

Artificial Tears Account for 37.8% Share

Artificial Tears are projected to account for 37.8% of the Product Type segment in 2026, making them the leading product category.

Their position reflects familiarity. Consumers generally understand artificial tears as a direct response to dryness and irritation, which reduces the time required to make a purchase decision.

The category includes preserved and preservative-free artificial tears, gel-based products, lubricating eye drops, hyaluronic acid drops, carboxymethylcellulose drops, and glycerin-based formulations.

Gel-based products can serve consumers looking for longer-lasting surface comfort, while specialized formulations provide manufacturers with opportunities to differentiate within an otherwise familiar category.

Preservative-Free Formulations Lead With 45.8%

Preservative-free formulations are expected to hold 45.8% of the Formulation segment in 2026.

Repeat users have a greater incentive to examine formulation characteristics. When eye drops become part of a daily routine, comfort, dosing frequency, bottle design, and preservative considerations can influence brand selection.

Single-dose vials offer a hygiene-focused format, while multi-dose preservative-free bottles provide convenience for consumers who prefer not to dispose of individual vials after each use.

This shift creates a formulation opportunity for manufacturers. However, higher production and packaging costs can translate into a price premium, potentially limiting adoption among price-sensitive consumers.

Retail Pharmacies Hold 35.5% Share

Retail Pharmacies are anticipated to account for 35.5% of the Distribution Channel segment in 2026.

Pharmacy shelves provide immediate access to non-prescription eye-care products. They also give consumers an opportunity to compare brands, formulations, package sizes, and symptom-oriented product descriptions before purchasing.

Chain pharmacies and independent pharmacies can influence selection through pharmacist guidance. Drug stores provide another convenience-led channel for replacement purchases.

Online retail is gaining relevance for established users who already know which product they prefer. Digital purchasing can make repeat ordering easier, particularly for consumers using eye drops regularly.

Evaporative Dry Eye Represents 40.6%

Evaporative Dry Eye is estimated to represent 40.6% of the Application segment in 2026.

The application category is shaped by tear-film instability and recurring ocular discomfort. Meibomian gland dysfunction creates another important use case, while contact-lens-related and environmental dry eye expand the occasions for OTC lubrication.

Lipid-based drops and emulsion formulations offer manufacturers another route to address consumers whose symptoms are associated with tear-film instability rather than simple lack of lubrication.

Digital eye strain also broadens the potential consumer base. The market is therefore no longer limited to traditional age-related dry-eye use cases.

Adults Represent 40.8% of End Users

Adults are forecast to account for 40.8% of the End User segment in 2026.

Working professionals create recurring use cases through long screen-based workdays. Senior consumers contribute demand associated with age-related irritation, while contact-lens wearers represent a more targeted group seeking lubrication and comfort.

The breadth of the adult consumer base makes packaging communication especially important. Products need to distinguish dryness relief from unrelated eye-care categories such as redness relief.

Clear labels can reduce confusion at the shelf. This becomes increasingly relevant as manufacturers introduce specialized formulations with different intended uses.

What Is Driving the OTC Dry Eye Drops Market?

Familiarity with artificial tears remains a primary demand driver. Consumers already recognize the category, making artificial tears an accessible starting point for self-care.

Preservative-free conversion is another growth factor. Repeat users may increasingly compare preservative-free products when comfort becomes part of their daily eye-care routine.

Retail pharmacy access provides an additional advantage. Immediate product availability reduces search time and allows shoppers to obtain relief without waiting for a clinical appointment.

Digital eye strain creates a wider demand base. Consumers spending extended periods on computers and smartphones can experience recurring eye discomfort, increasing awareness of OTC lubrication products.

Price Premiums and Safety Confidence Remain Challenges

The market also faces practical constraints.

Preservative-free products can carry a higher price because of formulation and packaging requirements. Some consumers may therefore remain with conventional preserved products despite growing interest in preservative-free alternatives.

Product safety is another critical consideration. The 2024 FDA-published recall amendment involving certain lubricant eye drops demonstrates how manufacturing and distribution issues can affect consumer confidence in ophthalmic products.

Packaging clarity presents a separate challenge. Consumers can confuse lubricating eye drops with redness-relief products when labels do not clearly communicate the intended use.

“In the OTC dry eye drops market the practical test is whether a product gives clear relief cues without confusing shoppers at the shelf. Buyers are asking brands to support comfort claims with safe packaging and reliable repeat availability,” said Shambhu Nath Jha, Sr. Consultant at Fact.MR.

Preservative-Free and Lipid-Based Products Create Opportunities

Manufacturers have several avenues for differentiation.

Preservative-free multipacks can reduce repeat-purchase friction among established users. Single-dose and multi-dose formats can serve different convenience requirements.

Online pharmacy refill pathways provide another opportunity. Consumers who have already selected a preferred eye drop can use digital channels to simplify repeat purchasing.

Lipid-based formulations could gain attention among evaporative dry-eye users seeking tear-film support beyond conventional lubrication.

A further opportunity exists in clinic-to-retail handoffs. Eye-care professionals can influence product selection, while consumers can continue maintenance through OTC channels after receiving appropriate guidance.

United States Leads Country Growth at 7.8% CAGR

The United States is projected to expand at a 7.8% CAGR from 2026 to 2036, the fastest growth rate among the countries listed in the Fact.MR comparison.

Broad pharmacy coverage supports accessibility, while online purchasing can facilitate repeat orders. Artificial tears also benefit from strong consumer familiarity in the U.S. market.

Germany follows at 7.1% CAGR, supported by disciplined product selection and pharmacy-led purchasing. The United Kingdom is projected to grow at 6.3%, where pharmacy guidance plays an important role.

France is expected to record 5.7% CAGR, while Japan is projected at 5.0%. Canada is forecast to expand at 4.2% CAGR, with broad retail-pharmacy access supporting adoption.

Who Are the Key Companies?

The competitive landscape includes established eye-care companies with consumer products, ophthalmic portfolios, and retail distribution capabilities.

Fact.MR profiles Alcon Inc., Bausch + Lomb, AbbVie Inc., Santen Pharmaceutical Co., Ltd., Rohto Pharmaceutical Co., Ltd., and Thea Pharmaceuticals.

Alcon and Bausch + Lomb have direct relevance through established eye-care and lubricant product portfolios. AbbVie contributes broader dry-eye treatment expertise, while Santen and Rohto bring established ophthalmology and consumer eye-care positions.

Competition is expected to center on formulation comfort, preservative-free positioning, packaging, safety confidence, availability, and ease of product selection.

Product innovation is also influencing the broader OTC eye-care category. On April 26, 2024, Bausch + Lomb announced FDA approval of LUMIFY Preservative Free, an OTC preservative-free eye drop for ocular redness, demonstrating continued industry interest in preservative-free ophthalmic formats.

Market Snapshot

2025 Market Value: USD 4.6 billion
2026 Market Value: USD 4.9 billion
2036 Forecast Value: USD 8.8 billion
CAGR, 2026–2036: 6.0%
Absolute Dollar Opportunity: USD 3.9 billion
Leading Product Type: Artificial Tears, 37.8%
Leading Formulation: Preservative-free Formulations, 45.8%
Leading Distribution Channel: Retail Pharmacies, 35.5%
Leading Application: Evaporative Dry Eye, 40.6%
Leading End User: Adults, 40.8%
Fastest-Growing Listed Country: United States, 7.8% CAGR
Germany: 7.1% CAGR
United Kingdom: 6.3% CAGR
France: 5.7% CAGR
Japan: 5.0% CAGR
Canada: 4.2% CAGR
Key Companies: Alcon Inc., Bausch + Lomb, AbbVie Inc., Santen Pharmaceutical Co., Ltd., Rohto Pharmaceutical Co., Ltd., Thea Pharmaceuticals
Unlock Actionable Insights from the Complete Report: https://www.factmr.com/report/otc-dry-eye-drops-market

Report Scope and Methodology

Fact.MR's OTC Dry Eye Drops Market study covers non-prescription lubricating eye drops used for dry-eye relief and daily comfort. The scope includes artificial tears, preservative-free and preserved formulations, gel-based products, lipid-based eye drops, natural formulations, and related OTC lubrication products.

The study evaluates the market by Product Type, Formulation, Distribution Channel, Application, End User, and Region. Coverage includes retail pharmacies, online retail, hospital pharmacies, supermarkets and other consumer channels where relevant to OTC purchases.

The analysis draws on 120+ sources, 35+ company portfolios, 25+ countries, and more than 20 industry interviews. Primary research includes manufacturers, distributors, end users, procurement teams, service providers, and subject-matter experts.

Fact.MR combines demand indicators with product-type mix, preservative-free adoption, retail pharmacy reach, online refill behavior, application needs, country adoption patterns, and company portfolio analysis. Findings are validated against public data and company activity before market estimates are finalized.

Explore More Related Studies Published by Fact.MR Research:\

Baby Nasal Aspirator Market- https://www.factmr.com/report/baby-nasal-aspirator-market

Buccal Fat Removal Market- https://www.factmr.com/report/buccal-fat-removal-market

Heart Lung Machine Market- https://www.factmr.com/report/heart-lung-machine-market

Vitamin D Therapy Market- https://www.factmr.com/report/vitamin-d-therapy-market

X-Ray Irradiation Market- https://www.factmr.com/report/x-ray-irradiation-market

About Fact.MR

Fact.MR is an initiative of Eminent Research and Advisory Services, an independent market research and consulting firm providing syndicated research, custom research, and strategic consulting across healthcare, technology, food and beverage, chemicals and materials, industrial goods, consumer goods, and other major industries.

Fact.MR serves clients globally through offices in Rockville, Maryland, and Dublin, Ireland.

Media Contact

Fact.MR
11140 Rockville Pike, Suite 400
Rockville, MD 20852, United States
Tel: +1 (628) 251-1583
Email: [email protected]

Dublin Office:
Suite 9884, 27 Upper Pembroke Street
Dublin 2, Ireland
Tel: +353-1-4434-232

Disclosure

This release is based on Fact.MR syndicated research. Market figures represent estimates and forecasts available as of the publication date and may be revised as additional information becomes available.